Using novel oxidative phosphorylation inhibitors to attenuate drug resistance in human gliomas
EXCLI Journal · 12.03.2025 · 24 · 433-449
DOI: 10.17179/excli2025-8193 ↗Kurz gefasst
Fachartikel in der Zeitschrift EXCLI Journal, online erschienen am 12.03.2025. Verfasst von Chia-Kuang Tsai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glioblastoma multiforme (GBM) is an aggressive brain tumor with a poor prognosis, worsened by resistance to temozolomide (TMZ). TMZ-induced DNA damage is counteracted by the repair enzyme O-6-methylguanine-DNA methyltransferase (MGMT), promoting tumor recurrence. Targeting oxidative phosphorylation (OXPHOS), essential for cellular energy production, offers a potential therapeutic strategy to overcome TMZ resistance and improve GBM treatment outcomes. Gboxin, a small-molecule drug, selectively inhibits OXPHOS by targeting complex V, with minimal toxicity to normal cells. It accumulates in the mitochondria of GBM cells, exploiting their high membrane potential and pH, thereby inhibiting cell proliferation. This study evaluates Gboxin's efficacy in TMZ-resistant (TMZ-R) GBM. Results show that Gboxin suppresses the growth of both TMZ-sensitive and TMZ-R GBM cells by inhibiting proliferation, inducing apoptosis, and reducing OXPHOS activity. These findings were confirmed in an in vivo model, highlighting Gboxin as a promising therapeutic for both TMZ-sensitive and TMZ-R GBM.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
- Department of Biochemistry, National Defense Medical Center, Taipei 11490, Taiwan.
- Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, 11490, Taiwan.
Zitieren
APA
Tsai, C. K., Lin, C. Y., Chang, Y. L., Yang, F. C., Chou, C. H., Huang, Y. C., & Hueng, D. Y. (2025). Using novel oxidative phosphorylation inhibitors to attenuate drug resistance in human gliomas. EXCLI Journal, 24, 433-449. https://doi.org/10.17179/excli2025-8193
Vancouver
Tsai CK, Lin CY, Chang YL, Yang FC, Chou CH, Huang YC, et al. Using novel oxidative phosphorylation inhibitors to attenuate drug resistance in human gliomas. EXCLI Journal. 2025;24:433-449. doi:10.17179/excli2025-8193
BibTeX
@article{Tsai2025,
author = {Tsai, Chia-Kuang and Lin, Chin-Yu and Chang, Yung-Lung and Yang, Fu-Chi and Chou, Chung-Hsing and Huang, Yu-Chian and Hueng, Dueng-Yuan},
title = {Using novel oxidative phosphorylation inhibitors to attenuate drug resistance in human gliomas},
journal = {EXCLI Journal},
year = {2025},
volume = {24},
pages = {433--449},
doi = {10.17179/excli2025-8193}
}
EUVIMED